Phase 3
Completed N=100
Exparel Use in Adductor Canal Block After Total Knee Arthroplasty
Arthritis Knee · Pain, Postoperative · Opioid Use Disorder
Source: ClinicalTrials.gov NCT04910165 ↗
Enrolled (actual)
100
Serious AEs
0.0%
Results posted
May 2022
Primary outcomePrimary: Hospital Length of Stay — 36.3; 49.7 Hours — p=<0.05
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Exparel has been shown to have better pain control compared to previously used infiltration agents, including bupivacaine, while having a minor side effect profile. The purpose of this study is to explore the effectiveness of Exparel (liposomal bupivacaine) in Adductor Canal Blocks for peri-operative pain control following a total knee arthroplasty (TKA) procedure.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Hospital Length of Stay |
36.3; 49.7 | <0.05 sig |
| PRIMARY Inpatient Opioid Use |
40.9; 47.3 | <0.05 sig |
| PRIMARY Numeric Rating Scale (NRS) Pain Score Improvement |
1.8; -0.2; 1.0; -1.3; 2.3; -0.1 | <0.05 sig |
| PRIMARY Outpatient Opioid Use |
33.4; 32.1 | <0.05 sig |
| PRIMARY WOMAC Score |
4.0; 1.2; 1.5; 0.2; 14.8; 4.6 | <0.05 sig |
| SECONDARY Number of Participants Needing to be Readmitted to the Hospital Secondary to Inadequate Pain Control Post-operatively |
2; 6 | <0.05 sig |
| SECONDARY Number of Participants Needing to be Admitted to an Inpatient Rehabilitation Facility Post-Operatively |
3; 4 | <0.05 sig |
Eligibility Criteria
Inclusion Criteria
- Patients were eligible for inclusion if they were undergoing unilateral primary TKA for a diagnosis of knee osteoarthritis and were not undergoing any additional concomitant procedures were.
Exclusion Criteria
- Patients were not eligible for our study if they were undergoing revision TKA, if they were undergoing bilateral TKA or concomitant procedures, or if they had an active infection.
Data sourced from ClinicalTrials.gov (NCT04910165). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.